MILAN — Older patients with acute myeloid leukemia (AML) had “clinically meaningful improvement” in survival when treated with azacitidine instead of conventional therapy, although the benefit did not achieve statistical significance, a randomized trial showed.

Azacitidine-treated patients had a median survival of 10.4 months versus 6.5 months for patients treated with conventional regimens. The difference increased to a statistically significant 5 months with censoring of survival data at the start of subsequent AML therapy, reported Hervé Dombret, MD, of Hôpital Saint Louis in Paris, and colleagues.

READ FULL ARTICLE Curated publisher From Medical Page Today